Seattle Biologics Firm Offers COVID-19 ‘Vaccine’ OTC Before Warnings By State, Federal Agencies

When businesses rapidly pivot to offering consumer health products and services, they’re likely not contemplating compliance with FDA regulations. Recent warning letters are more proof COVID-19 represents opportunities for numerous businesses that aren’t prepared to follow or simply aren’t aware of FDA regulations.

Coronavirus dollar bill

Some recent recipients of US Food and Drug Administration warnings probably wouldn’t have any reason to anticipate contact from the agency if they weren’t attempting to capitalize on consumer fear about COVID-19. When businesses rapidly pivot to offering consumer health products and services, though, they’re likely not contemplating compliance with the FDA’s regulations.

Recent warning letters the agency published are more proof that the novel coronavirus 2019 represents opportunities for numerous businesses and...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Compliance

More from Policy & Regulation